Regional COVID Epidemiology in England (RECEDE)
RECEDE
Regional Epidemiology of COVID-19 and Acute Kidney Injury in England
1 other identifier
observational
5,000
0 countries
N/A
Brief Summary
The COVID-19 pandemic has exposed the unwanted variation in outcomes as evidence by Public Health England's report on increased mortality in regions of the country. For example, UHDB, in East Midlands, has reported a high crude mortality as compared to other Trusts in the region.8 There may also have been variation in the incidence of complications of COVID-19 in the form of AKI, which may have influenced mortality. Variation in outcomes may be because of various factors - differing population demographics, underlying health conditions in the population, deprivation, physician preference and knowledge and ethnic diversity. Unwanted variation is care that is not consistent with a patient's preference or related to \[their\] underlying illness. It is important to understand the reason for unwanted variation in outcomes associated with COVID-19 to minimise patient harm and reduce morbidity and mortality.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2020
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 6, 2020
CompletedFirst Posted
Study publicly available on registry
October 8, 2020
CompletedStudy Start
First participant enrolled
November 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 31, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
October 31, 2021
CompletedOctober 8, 2020
October 1, 2020
5 months
October 6, 2020
October 6, 2020
Conditions
Outcome Measures
Primary Outcomes (2)
All-cause mortality
In-hospital all cause mortality in patients with acute kidney injury and COVID-19
30 days
acute kidney injury
Incidence of acute kidney injury in patients with COVID-19
30 days
Secondary Outcomes (1)
Mechanical ventilation
30 days
Study Arms (3)
COVID-19 positive AKI
COVID-19 positive no AKI
COVID negative AKI
Interventions
This is observational, non-interventional study
Eligibility Criteria
We will use analysis of all admitted patients in the past in England between 1st March 2020 and 30th June 2020 from the Hospital Episode Statistics (HES), a data warehouse containing details of all admissions at NHS hospitals in England. This design will help to analyse large number of AKI patients in short time-span so as to cascade the learning in timely fashion. HES collects a detailed record for each admitted patient care delivered in England, either by NHS hospitals. In each patient record, there are specific codes for additional diagnosis, or operations. We will extract all patients with diagnosis of COVID-19 by ICD-10 code of U07.1 and AKI as identified by ICD-10 code of N17 in any of the 20 diagnostic codes during the study period.
You may qualify if:
- This study will have two work packages (WP). Work Package 1 (WP1): Regional epidemiology of COVID-19 in England All patients who are admitted to hospital with COVID-19 infection between 1st March 2020 and 30th June 2020 and who meet following criteria will be included
- Diagnostic code for COVID-19 (U07.1) in any of the 20 diagnoses codes
- Adult patients greater or equal to 18 years of age.
- Work Package 2 (WP2): Epidemiology of COVID-19 associated AKI in England All patients who are admitted to hospital with acute kidney injury (AKI) between 1st March 2020 and 30th June 2020 and who meet following criteria will be included
- Diagnostic code for AKI (N17) in any of the 20 diagnoses codes
- Adult patients greater or equal to 18 years of age.
You may not qualify if:
- WP1:
- The following patients will be excluded from the study
- Patients not admitted to the hospital
- Paediatric patients \< 18 years of age
- WP2:
- The following patients will be excluded from the study
- Patients not admitted to the hospital
- Paediatric patients \< 18 years of age
- Patients on chronic maintenance haemodialysis or peritoneal dialysis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (2)
Kolhe NV, Fluck R, Taal M. Effect of COVID-19 with or without acute kidney injury on inpatient mortality in England: a national observational study using administrative data. BMJ Open. 2025 Mar 15;15(3):e095020. doi: 10.1136/bmjopen-2024-095020.
PMID: 40090681DERIVEDKolhe NV, Fluck RJ, Taal MW. Regional variation of COVID-19 admissions, acute kidney injury and mortality in England - a national observational study using administrative data. BMC Infect Dis. 2024 Mar 22;24(1):346. doi: 10.1186/s12879-024-09210-6.
PMID: 38519921DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 6, 2020
First Posted
October 8, 2020
Study Start
November 1, 2020
Primary Completion
March 31, 2021
Study Completion
October 31, 2021
Last Updated
October 8, 2020
Record last verified: 2020-10
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- 6 months